Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $408.5 million.

  • Cartesian Therapeutics' Total Liabilities fell 1012.95% to $408.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $408.5 million, marking a year-over-year decrease of 1012.95%. This contributed to the annual value of $441.8 million for FY2024, which is 64.2% down from last year.
  • According to the latest figures from Q3 2025, Cartesian Therapeutics' Total Liabilities is $408.5 million, which was down 1012.95% from $391.4 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Total Liabilities registered a high of $454.6 million during Q3 2024, and its lowest value of $45.7 million during Q3 2023.
  • Its 5-year average for Total Liabilities is $248.5 million, with a median of $185.9 million in 2021.
  • In the last 5 years, Cartesian Therapeutics' Total Liabilities tumbled by 5419.04% in 2022 and then surged by 89456.08% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Total Liabilities (Quarter) stood at $137.4 million in 2021, then plummeted by 47.54% to $72.1 million in 2022, then surged by 517.11% to $444.7 million in 2023, then dropped by 0.64% to $441.8 million in 2024, then decreased by 7.54% to $408.5 million in 2025.
  • Its Total Liabilities stands at $408.5 million for Q3 2025, versus $391.4 million for Q2 2025 and $430.9 million for Q1 2025.